Biography
Ph.D. Computational Chemistry, Nanjing Univ, 1990 2007-present: Chemist, NCTR, FDA 2002-2007: Manager of Bioinformatics, Northrop Grumman Co. at NCTR/FDA 2000-2002: Scientist, Federal Data Co. at NCTR/FDA 1998-2000: Scientist, Sumitomo Chemical Co., Ltd., Japan 1995-1998: Visiting Scientist, NCI/NIH
Research Interest
Next-generation sequencing: technical robustness and variation of data analysis; Genome-wide association studies (GWAS): baseline practices for analyzing GWAS data, technical robustness of genotyping technology, sources of spurious associations, batch effects in GWAS; Proteomics: quality control and quality assessment of proteomics data, biomarkers for detecting hepatotoxicity, prediction protein function from protein sequences; Genomics: development of classifiers of diagnosis and prognosis based on gene expression profiles. Chemoinformatics: estrogenic activity database
Biography
Dr. Anthony Boey obtained his Ph.D. at Simon Fraser University in the area of Biophysics/polymer chemistry, and is the Head of Formulation Development at CDRD. With over 20 years of industrial drug development experience, Dr. Boey has expertise in the areas of pre-formulation, formulation optimization, process scale-up and cGMP manufacturing. His drug delivery experience includes nanoparticles (e.g. liposomes, polymeric micelles), polymeric depots , oral dosage, inhalation and topicals. Dr. Boey is an inventor in a number of (issued) drug delivery associated patents. Prior to joining CDRD, Dr. Boey has held positions of postdoctoral fellow (Inex Pharmaceuticals), Senior Scientist (Angiotech Inc., QLT Inc.), Manager of Clinical Manufacturing (Northern Lipids) and most recently, was Head of Formulations (Generic Injectables) at Mylan Inc. (Ireland).
Research Interest
His drug delivery experience includes nanoparticles (e.g. liposomes, polymeric micelles), polymeric depots , oral dosage, inhalation and topicals.
Biography
Dr. Farid Menaa is an inter- and multi-disciplinary professional with worldwide reputation. He has three international post-doctoral terms in Oncology, Dermatology, and Hematology; MBA Entrepreneurship and MD candidate. During his ongoing career, he has mainly contributed to the identification and functions of new human disease-causing genes and variants, formulated natural products for anti-aging and developed innovative theranostic strategies against cancers, cardiovascular diseases, diabetes, obesity and infectious diseases. He has more than 10 years’ experiences either in the academic, hospitals or industrial sectors. As Chief Scientific Officer and Vice-President R&D at Fluorotronics, Inc. he actively participated in the development of the disruptive “Carbon-Fluorine Spectroscopyâ€. Dr. Menaa collaborates with various organizations worldwide. He is a member of several prestigious medical and scientific organizations and editorial boards in the field of medicine, science, technology and business, including in the nano-segment. He has authored more than 100 articles including research and review articles, books, book chapters, textbooks, proceedings, and has participated to over 200 scientific international events including as co-organizer, keynote speaker, chairman. Dr. Menaa’s worldwide collaborations, holistic point of view and strong expertise in various fields led him to prevent, implement early diagnosis, and develop efficient and safer therapy.
Research Interest
Dr. Farid Menaa’s research interest includes Preventive Medicine, Personalized Medicine, Translational Medicine, Integrative Medicine, Green Medicine, Nanomedicine, Biotechnology, and Nanotechnology